Clinical Trials Logo

Peripheral Artery Disease clinical trials

View clinical trials related to Peripheral Artery Disease.

Filter by:

NCT ID: NCT02121288 Withdrawn - Clinical trials for Peripheral Artery Disease

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

PAD
Start date: December 2014
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with Peripheral Artery Disease (PAD).

NCT ID: NCT01809730 Withdrawn - Hypertension Clinical Trials

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

Start date: May 2012
Phase: N/A
Study type: Observational

This is a non-randomized, non-interventional pilot observational study designed to follow high-risk patients through their surgical and hospital stay. The investigators will collect 2 4ml vial's of blood (total of 8ml) prior to surgery to assess CV biomarkers - inflammatory, metabolic, hypercoagulable and platelet.

NCT ID: NCT00771797 Withdrawn - Clinical trials for Peripheral Artery Disease

Peripheral Artery Occlusive Diseases (PAOD) Study - Clinical Assessment

Start date: October 2008
Phase: Phase 2
Study type: Interventional

To assess the clinical efficacy and to simultaneously explore the underlying molecular mechanisms of the beneficial effects of flavanol-rich cocoa on vascular function diabetic patients with peripheral artery occlusive diseases (PAOD) of the lower extremities will be investigated.

NCT ID: NCT00569686 Withdrawn - Clinical trials for Peripheral Artery Disease

Lovaza Therapy of Peripheral Arterial Disease

Start date: September 2007
Phase: N/A
Study type: Interventional

Sixty patients with mild-to-moderate PAD (ABI 0.4-0.9) and hypertriglyceridemia (>200 mg/dl) already treated with statins will be imaged at baseline and randomized to Lovaza and placebo for 12 months. MR imaging will be repeated at the end of the 12-month period. We hypothesize that treatment of hypertriglyceridemia in patients with PAD with Lovaza will reduce atherosclerotic plaque volume in the superficial femoral artery (SFA) by 2% over 1 year compared to placebo. Secondary aims will be to show improved plaque characteristics (thickened fibrous cap, reduced lipid-rich necrotic core, improved exercise calf muscle perfusion using first-pass contrast enhanced MRI and improved exercise treadmill performance with Lovaza compared to matching placebo.